Literature DB >> 31345628

Management of high-risk endometrial cancer: are we there yet?

Marcus Randall1.   

Abstract

Entities:  

Year:  2019        PMID： 31345628     DOI： 10.1016/S1470-2045(19)30416-4

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

1.  Postoperative Adjuvant Chemoradiotherapy Versus Chemotherapy Alone for Stage III Endometrial Cancer: A Multicenter Retrospective Study.

Authors:  Ji Geun Yoo; Jin Hwi Kim; Chan Joo Kim; Hae Nam Lee; Min Jong Song; Dong Choon Park; Joo Hee Yoon; Sang Il Kim; Soo Young Hur; Sung Jong Lee
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 2.339

2.  Adjuvant chemotherapy in early-stage endometrioid endometrial cancer with >50% myometrial invasion and negative lymph nodes.

Authors:  Francesco Multinu; Simone Garzon; Amy L Weaver; Michaela E McGree; Enrico Sartori; Fabio Landoni; Paolo Zola; Giorgia Dinoi; Giovanni Aletti; Matthew S Block; Angiolo Gadducci; Andrea Mariani
Journal:  Int J Gynecol Cancer       Date:  2021-02-19       Impact factor: 3.437

3.  IGF2BP1 overexpression stabilizes PEG10 mRNA in an m6A-dependent manner and promotes endometrial cancer progression.

Authors:  Lin Zhang; Yicong Wan; Zihan Zhang; Yi Jiang; Zhiyue Gu; Xiaoling Ma; Sipei Nie; Jing Yang; Jinghe Lang; Wenjun Cheng; Lan Zhu
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.